Proniosomes as a carrier system for transdermal delivery of tenoxicam

Ammar, H. O.; Ghorab, Mahmoud M.; El-Nahhas, S. A.; Higazy, Iman M.

doi:10.1016/j.ijpharm.2010.11.003

Cited by 107 publications

(71 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, it was equilibrated in phosphate buffer solution (pH 7.4) for 1 h prior to the experiment and sandwiched between the two compartments such that the stratum corneum side and the dermis of the skin were towards the donor and receptor compartments of the Franz diffusion cell (diffusion area: 2.26 cm 2 and volume: 25 ml), respectively. [11] The receptor medium consisted of 25 ml mixture of ethanol: phosphate buffer (30:70 v/v). [23] To simulate the in vivo conditions, the proniosomal gel (eq.…”

Section: Skin Permeation Studiesmentioning

confidence: 99%

“…[10] Transdermal delivery of tenoxicam by proniosomes has been reported to significantly enhance the anti-inflammatory and analgesic effects as compared to the marketed tablets. [11] Similarly, the in vivo efficacy of mefenamic acid has been improved with proniosomal gel. [12] A considerable advance in this field has been observed in the delivery of anti-arthritic therapeutics due to the combination of topical and systemic effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Proniosomal gel-mediated transdermal delivery of bromocriptine:in vitroandex vivoevaluation

Lather¹,

Sharma²,

Pandita³

2016

Journal of Experimental Nanoscience

View full text Add to dashboard Cite

Vesicular systems endow large opportunities for the transdermal delivery of therapeutics. The present study was designed to investigate the potential of a novel class of vesicular system 'proniosome' as a carrier for transdermal delivery of bromocriptine (BCT). Proniosome formulations were prepared by the coacervationphase separation method and the influence of factors like surfactant type and its amount, lipid concentration, cholesterol amount and drug content were studied. Span 60 was the most appropriate surfactant, and yielded vesicle size and percentage encapsulation efficiency of 1.3 mm and 98.9%, respectively. The developed system was characterised w.r.t. morphology, transition temperature, drug release, skin permeation and skin irritancy. Proniosomes exhibited a sustained release pattern of BCT in vitro. Skin permeation study revealed high penetration of proniosomes with sustained release of BCT through rat skin. The optimised proniosomal formulation showed enhanced transdermal flux of 16.15 mg/cm 2 /h as compared to 3.67 mg/cm 2 /h for drug dispersion. The developed formulations were observed as non-irritant to the rat skin and were found as quite stable at 4 and 25 C for 90 days w.r.t. vesicle size and drug content. The dried proniosomal formulation could act as a promising alternative to niosomes and preferably for transdermal delivery of BCT.

show abstract

Section: Skin Permeation Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Proniosomal gel-mediated transdermal delivery of bromocriptine:in vitroandex vivoevaluation

Lather¹,

Sharma²,

Pandita³

2016

Journal of Experimental Nanoscience

View full text Add to dashboard Cite

show abstract

“…Manosroi et al (2008) obtained a higher flux of the drug in SC and deeper dermal tissues (live epidermis and dermis) with elastic noisome formulations loaded with diclophenac diethylammonium. Niosome-like vesicles consisting of hydrated mixtures of cholesterol and non-ionic surfactants are defined as "proniosomes" (Alsarra et al, 2005;Ammar et al, 2011). Alsarra et al (2005) demonstrated that proniosomes of ketorolac improves permeation of the drug and shortens its lag time.…”

Section: Niosomesmentioning

confidence: 99%

“…In another study, formulations of proniosome were developed for transdermal delivery of tenoxicam. It has been stressed that proniosome formulation loaded with tenoxicam had higher anti-inflammatory and analgesic effect than the commercially available tenoxicam tablets (Ammar et al, 2011).…”

Section: Niosomesmentioning

confidence: 99%

Novel Formulation Approaches for Dermal and Transdermal Delivery of Non-Steroidal Anti-Inflammatory Drugs

Okyar¹,

Özsoy²,

Güngör³

2012

Rheumatoid Arthritis - Treatment

View full text Add to dashboard Cite

“…Compared with other H 2 receptor antagonists, it is 7.5 and 20 times more potent than ranitidine and cimetidine, respectively. [9] Famotidine is relatively free of side effects despite of its high potency. In spite of its benefits, famotidine suffered from low and variable bioavailability (20%À40%) and short biological half-life (2.5À4 hours).…”

Section: Introductionmentioning

confidence: 99%

Formulation and optimisation of famotidine proniosomes: anin vitroandex vivostudy

Mokale

Patil

et al. 2015

Journal of Experimental Nanoscience

View full text Add to dashboard Cite

The aim of the study was to develop a proniosomal system for famotidine (FAM), a potent H 2 receptor antagonist that could efficiently deliver entrapped drug over a prolonged period of time. The proniosomal system was formulated by selecting various ratios of Span 60 and cholesterol using a coacervation-phase separation method. The formulated systems were characterised for drug excipient compatibility studies by Fourier transform infrared spectroscopy (FTIR), vesicle size determination by the particle size analyser, % drug encapsulation, drugrelease profiles, field emission scanning electron microscopy (FESEM) for surface morphology, X-ray diffraction (XRD) and vesicular stability at different storage conditions. By using this method, the % drug loading that resulted by the encapsulation of proniosome was found to be 78%À89%. Increase in cholesterol and surfactant concentration increases encapsulation efficiency, but further increment decreases encapsulation. In vitro drug-release studies showed prolonged release of entrapped famotidine. The highest % cumulative drug release was achieved in formulation FAM2 (96%) in 24 hours. The ex vivo data on the release of famotidine from proniosomal formulations have shown significantly increased per cent release and flux in comparison to the same dose of marketed preparation of famotidine. Stability studies were carried out in refrigerated conditions, and higher drug retention was observed. It is evident from this study that proniosomes are a promising prolonged delivery system for famotidine and have reasonably good stability characteristics.

show abstract

Proniosomes as a carrier system for transdermal delivery of tenoxicam

Cited by 107 publications

References 42 publications

Proniosomal gel-mediated transdermal delivery of bromocriptine:in vitroandex vivoevaluation

Proniosomal gel-mediated transdermal delivery of bromocriptine:in vitroandex vivoevaluation

Novel Formulation Approaches for Dermal and Transdermal Delivery of Non-Steroidal Anti-Inflammatory Drugs

Formulation and optimisation of famotidine proniosomes: anin vitroandex vivostudy

Contact Info

Product

Resources

About